Sadly, terrorism is a real threat to the United States homeland as we just saw last week. However, we can take a little solace in the fact that the recent terrorist attack involved crude homemade non-radiological bombs. The fact remains…
Tag: biopharma
Weekend update with some charts, Market forecast and opinion. (VIDEO)
Weekend update with some charts, $AVEO $ATRS $ARNA $ACRX briefly covered. Market forecast and opinion. YouTube Video
AVEO Poised To Move Higher Before FDA Adcomm Catalyst, Obamacare And Platform Potential
The advent of The Affordable Care Act (Obamacare) is on the horizon as the healthcare sector of the market continues its strong rally. With new Food and Drug Administration (FDA) regulatory easing, congressional bills, and The Obama Administration directive in…
AVEO Pharma’s Tivozanib Likely To Be Approved
With the current record market run, small cap biopharmas have kept pace and continue to trend higher, being one of the best sectors for both trading and investing over the past year. With 39 new drugs approved, 2012 showed the…
Valeant Acquires Obagi, Which Biotechs Are Next?
Yesterday, Obagi Medical Products (OMPI) was acquired by Valeant Pharmaceuticals (VRX) for $19.75 a share in an all cash deal. Last summer I covered in depth, acquisition rumors regarding Obagi. At the time, good private sources of mine confirmed that…
AcelRx Pharma Selloff Caused By Error In Recent Press Release
On March 12th, Acelrx (ACRX) released a pr covering its last quarter’s earnings. In the pr, the company stated that it had cash to last only to Q3 of this year. However, in the official conference call minutes, the company…
Download $TSRX Analyst Report
Download Analyst Report on $TSRX HERE-TSRX-SunTrust-Robinson-Humphrey-Feb-12
Why the latest rally could be a bull trap
This week has been a strange market week for sure. I have held back on picks mainly because I want to see some clarity as I believe we are at a market top, and economic data has peaked out. Furthermore,…
GLOBE NEWSWIRE: Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia
HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has designated Pluristem’s PLacental eXpanded (PLX) cells orphan drug status…
UPDATED: Cyclacel Pharma: Undervalued With Its Potential Blockbuster Drug
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and…
